Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma

被引：210

作者：

Chen, Jiang ^{[1
]}

Jin, Renan ^{[1
]}

Zhao, Jie ^{[1
]}

Liu, Jinghua ^{[1
]}

Ying, Hanning ^{[1
]}

Yan, Han ^{[1
]}

Zhou, Senjun ^{[1
]}

Liang, Yuelong ^{[1
]}

Huang, Diyu ^{[1
]}

Liang, Xiao ^{[1
]}

Yu, Hong ^{[1
]}

Lin, Hui ^{[1
]}

Cai, Xiujun ^{[1
]}

机构：

[1] Zhejiang Univ, Dept Gen Surg, Sir Run Run Shaw Hosp, Hangzhou 310003, Zhejiang, Peoples R China

来源：

CANCER LETTERS | 2015年 / 367卷 / 01期

基金：

中国国家自然科学基金;

关键词：

Advanced hepatocellular carcinoma (HCC); Epithelial-mesenchymal transitions (EMT) and mesenchymal epithelial transitions (MET); Cancer stem cells (CSCs); Microenvironment; Acquired resistance; EPITHELIAL-MESENCHYMAL TRANSITION; HEDGEHOG SIGNALING PATHWAY; ALPHA-B-CRYSTALLIN; LIVER-CANCER CELLS; PHASE-III; PROMOTES METASTASIS; DEPENDENT MECHANISM; PLUS SORAFENIB; BREAST-CANCER; UP-REGULATION;

D O I：

10.1016/j.canlet.2015.06.019

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Sorafenib, an orally-available kinase inhibitor, is the only standard clinical treatment against advanced hepatocellular carcinoma. However, development of resistance to sorafenib has raised concern in recent years due to the high-level heterogeneity of individual response to sorafenib treatment. The resistance mechanism underlying the impaired sensitivity to sorafenib is still elusive though some researchers have made great efforts. Here, we provide a systemic insight into the potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma depending on abundant previous studies and reports. (C) 2015 Elsevier Ireland Ltd. All rights reserved.

引用

页码：1 / 11

页数：11

共 50 条

[41] Stabilization of snail maintains the sorafenib resistance of hepatocellular carcinoma cells
Zhao, Huan
Cheng, Xi
Yu, Judian
Li, Yong
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2021, 699
[42] YAP promotes sorafenib resistance in hepatocellular carcinoma by upregulating survivin
Sun, Ting
Mao, Wenhao
Peng, Hui
Wang, Qi
Jiao, Lin
CELLULAR ONCOLOGY, 2021, 44 (03) : 689 - 699
[43] A Novel atTAK Against Hepatocellular Carcinoma: Overcoming Resistance to Sorafenib
Pietrobono, Silvia
Melisi, Davide
CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY, 2021, 12 (03): : 1151 - 1152
[44] MiRNA Expression Profiling of Sorafenib Response and Resistance in Hepatocellular Carcinoma
Yousef, George
Butz, Henriett
Kerbel, Robert
Mozes, Roy
Patocs, Attila
Kerbel, Robert
MODERN PATHOLOGY, 2015, 28 : 200A - 201A
[45] Heat shock proteins in hepatocellular carcinoma: Molecular mechanism and therapeutic potential
Wang, Cun
Zhang, Yurong
Guo, Kun
Wang, Ning
Jin, Haojie
Liu, Yinkun
Qin, Wenxin
INTERNATIONAL JOURNAL OF CANCER, 2016, 138 (08) : 1824 - 1834
[46] Sorafenib induces conversion to RAF dependence and ERK activation as a mechanism of rapidly acquired resistance in hepatocellular carcinoma
Ramjiawan, Rakesh R.
Reiberger, Thomas
Chen, Yunching
Duyverman, Annique M.
Huang, Peigen
Flaherty, Keith
Zhu, Andrew X.
Jain, Rakesh K.
Duda, Dan G.
HEPATOLOGY, 2014, 60 : 650A - 650A
[47] Potential Treatment Strategies for Hepatocellular Carcinoma Cell Sensitization to Sorafenib
Jiang, Zhonghao
Dai, Chaoliu
JOURNAL OF HEPATOCELLULAR CARCINOMA, 2023, 10 : 257 - 266
[48] Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib
Yau, Thomas
Pang, Roberta
Chan, Pierre
Poon, Ronnie T.
EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (13) : 2187 - 2198
[49] Cancer Metabolism as a Mechanism of Treatment Resistance and Potential Therapeutic Target in Hepatocellular Carcinoma
Lee, Misu
Ko, Haeyong
Yun, Mijin
YONSEI MEDICAL JOURNAL, 2018, 59 (10) : 1143 - 1149
[50] Sorafenib in advanced hepatocellular carcinoma
Sauerbruch, T.
Gonzalez-Carmona, A. M.
Nitschmann, S.
INTERNIST, 2009, 50 (11): : 1290 - 1292

← 1 2 3 4 5 →